title: Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Goethe University Hospital, Frankfurt, Germany.|Liver Center Frankfurt, Goethe University Hospital, Frankfurt, Germany.|University Cancer Center, Goethe University Hospital, Frankfurt, Germany.
authors.forename: Joerg
authors.initials: J
authors.lastname: Trojan
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Goethe University Hospital, Frankfurt, Germany.|Liver Center Frankfurt, Goethe University Hospital, Frankfurt, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Sarrazin
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy*; D058625:End Stage Liver Disease / Q000150:complications; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy*; D000077594:Nivolumab; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab